

Outlook Therapeutics, Inc.

Q1 about inline. PDUFA goal date of August 29, 2023. Raising P/T to \$7.25.

COMPANY UPDATE

Rating: BUY

Ticker: OTLK

Price: \$1.05

Target: \$7.25
(from \$7.00)

Q1 about inline: Outlook recently (on February 14) reported its Q1 FY23 (ending December) results. EPS of \$(0.08) compared with our and consensus estimates of \$(0.06). There was no Q1 guidance. Outlook is a clinical stage medical device development/commercialization company so it generates minimal revenue.

Operating expense: Operating expenses were \$16 million, up \$2 million from Q4 mainly due to increased pre-commercialization work. Management declined to provide FY23 guidance. However, we believe ~\$14 million is a reasonable near term quarterly burn rate.

Adjusting estimates: We are adjusting our FY23 EPS estimate to \$(0.27) from \$(0.21).

PDUFA date of August 29, 2023: Outlook submitted its new BLA (Biologics License Application) to the FDA for ONS-5010 for treatment of wet AMD in Q4 FY22 (August 2022). In October, the FDA accepted its BLA and has set a Prescription Drug User Fee Act (PDUFA) goal (decision) date of August 29, 2023.

Positive clinical results: In August 2021, Outlook announced positive top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 for treatment of wet AMD. In March 2021, Outlook reported positive topline results from its NORSE THREE Open-Label Safety Study. In August 2020, Outlook reported topline results from its NORSE 1 study demonstrating safety and efficacy and positive proof-of-concept of ONS-5010 for the treatment of wet age-related macular degeneration (wet AMD).

ONS-5010 development on track: Outlook has one main therapeutic candidate, ONS-5010 (named LYTENAVA) which is a proprietary ophthalmic formulation of bevacizumab (Avastin) product for the treatment of wet AMD and other eye diseases. Avastin is FDA approved and used widely in oncology indications but is also used off-label for the treatment of several ophthalmic diseases. Outlook is developing LYTENAVA as a replacement for the use of off-label Avastin in the treatment of wet AMD.

FDA and EU approvals should be major positive catalysts: Potential FDA marketing approval is expected in August 2023 and for EU in early 2024.

Commercial launch in late 2023: Pending regulatory approvals, Outlook expects commercial launches shortly after FDA approval (likely to launch late 2023).

More studies planned: Outlook has received agreements from the FDA on three Special Protocol Assessments (SPAs) for three additional clinical trials. These SPAs cover ONS-5010 to treat branch retinal vein occlusion (BRVO), and for the treatment of diabetic macular edema (DME). These studies are planned to initiate in 2023 (after FDA approval for wet AMD).

Balance sheet: Outlook has \$53 million in cash and \$32 million in debt as of Q1 FY23. In Q1, it raised \$25 million selling stock (28 million shares at \$0.88) and \$32 million in debt. We believe it has enough cash through Q1 FY24.

Valuation attractive: Maintaining our BUY rating, but raising our 12-month price target to \$7.25 from \$7.00. This is based on a NPV analysis, representing significant upside from the current share price. We believe this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities.

Company Description

Based in Iselin, NJ, Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab (Avastin) product for the treatment of wet AMD.

Stock Data

Exchange:	NasdaqCM
52-week Range:	\$0.68 – 2.04
Shares Outstanding (million):	257
Market cap (\$million):	\$270
EV (\$million):	\$249
Debt (\$million):	\$32
Cash (\$million):	\$53
Avg. Daily Trading Vol. (\$million):	\$1
Float (million shares):	124
Short Interest (million shares):	15
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	2023E (Cur.)	2023E (Old)	2024E (Cur.)	2024E (Old)
Q1 Dec	0E		0E	
Q2 Mar	0E	1E	1E	
Q3 Jun	0E	1E	3E	
Q4 Sep	0E	3E	4E	
Total	0E	4E	8E	
EV/Revs	N/A		31x	

Earnings per Share (pro forma)

	2023E (Cur.)	2023E (Old)	2024E (Cur.)	2024E (Old)
Q1 Dec	(0.08)A	(0.06)E	(0.06)E	
Q2 Mar	(0.06)E	(0.06)E	(0.06)E	
Q3 Jun	(0.06)E	(0.06)E	(0.06)E	
Q4 Sep	(0.06)E	(0.04)E	(0.06)E	
Total	(0.27)E	(0.21)E	(0.23)E	
P/E	N/A		N/A	

Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 14.

Exhibit 1: Outlook’s Investment Highlights

Investment Highlights

FDA Market Approval of ONS-5010 (bevacizumab-vikg)¹, an Investigational Therapy for the Treatment of Wet AMD, Targeted for August 29, 2023 PDUFA Date

Targeting \$13.1 Billion Global Ophthalmic Anti-VEGF Market²

Differentiated Drug Product

- Designed to meet robust standards required for FDA ophthalmic approval
- Potential to eliminate risks associated with off-label repackaged bevacizumab, including potential impurities and particulates from compounders re-packaging processes
- Delivery ultimately expected through a convenient pre-filled syringe

Potential for 1st FDA Approved Ophthalmic Bevacizumab

- U.S. FDA BLA accepted with target PDUFA action date of August 29, 2023
- Potential U.S. launch in Q4 2023
- Received validation of Marketing Authorization Application by European Medical Agency
- Provides an economically elegant anti-VEGF solution for patients, payers and doctors

Attractive Market Opportunity

- Strategic commercialization agreement with AmerisourceBergen
- Over 50% of the U.S. market estimated to be available for conversion to ONS-5010, representing up to billions in potential yearly sales
- 12-years US regulatory exclusivity expected upon approval
- Label expansion opportunity into DME and BRVO


Source: Company reports.

Exhibit 2: Outlook’s ONS-5010 (LYTENAVA)

Standard of Care in Wet AMD

ONS-5010 / LYTENAVA™, if approved, will be the first on-label ophthalmic formulation of bevacizumab-vikg

- Anti-VEGF drugs have been standard of care since 2006
 - Block growth of abnormal blood vessels and leakage of fluid from the vessels behind the retina
- Several new clinical-stage anti-VEGF drugs, including biosimilars, in development and/or recently approved
 - Require significant time and capital to achieve commercialization
 - New drugs expected to price at or near the high price points of current approved therapies



Source: Company reports.

Exhibit 3: ONS-5010 (LYTENAVA) Market Opportunities

Unapproved Bevacizumab Represents 50% of U.S. Wet AMD Market Injections




Expected Drivers to Compete Across All Ophthalmic Anti-VEGF Therapeutics, if Approved by FDA

- 1 Provide cost-effective FDA approved ophthalmic bevacizumab
- 2 Become first-line "step-edit" drug of choice
- 3 12 years market exclusivity
- 4 Penetrate EU and developing markets

Targeting Large and Growing Ophthalmic Markets

ONS-5010, if Approved, Will Be a Significant Therapy In the Retinal Anti-VEGF Market, Currently Estimated To Be In Excess of \$13.1 Billion Worldwide



Source: Company reports.

Exhibit 4: ONS-5010 ((LYTENAVA) Planned Milestones

Compelling Clinical Data Support Potential FDA Approval in Wet AMD

- ✓ U.S. FDA BLA Accepted with Target PDUFA of August 29, 2023
- ✓ Received Validation of Marketing Authorization Application by European Medical Agency

✓ Positive Signals

NORSE ONE
Clinical Experience Trial
1st Registration Trial

✓ Positive Top-Line Data

NORSE TWO
Pivotal Trial
2nd Registration Trial

✓ Completed


NORSE THREE
Open-Label Safety Study
Supports BLA Requirements

Source: Company reports.

Exhibit 5: ONS-5010 ((LYTENAVA) Commercial Strategy

Charting a Path To a Successful Launch

Focus on Shaping the Market by Creating Awareness and Educating Physicians



Source: Company reports.


Exhibit 6: Recent Highlights and Upcoming Milestones (as of Q1 FY23 – February 14, 2023)

Recent Corporate Highlights

- Strengthened Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs, and Glen Olsheim, Executive Director of Commercial Excellence.
- Closed on approximately \$54 million in net proceeds from two financings to support pre-launch commercial activities through anticipated FDA approval of ONS-5010 in third calendar quarter of 2023 and into the fourth calendar quarter of 2023.
 - Approximately \$24 million registered direct equity offering priced at-the-market under Nasdaq rules.
 - Approximately \$30 million net proceeds from issuance of an unsecured convertible promissory note with an initial conversion price of \$2.00 per share.
- Received validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for ONS-5010/ LYTENAVA™ (bevacizumab-vikg).
- Announced that the FDA accepted its Biologics License Application (BLA) for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the treatment of wet AMD and set a PDUFA goal date of August 29, 2023.

Upcoming Anticipated Milestones

- Continued progress with ongoing pre-launch commercial preparations in anticipation of potential approval for ONS-5010 in 2023;
- PDUFA goal date of August 29, 2023;
- Completion of enrollment in the NORSE SEVEN clinical trial assessing the safety of ONS-5010 in a pre-filled syringe; and
- Estimated decision date from the EMA's CHMP on the Company's submitted MAA in EU for ONS-5010 expected in early 2024.



**Company
Summary**

- **Targeting \$13.1 billion global ophthalmic anti-VEGF market¹**
 - *Initial U.S. target segment worth up to billions in potential yearly revenue served by compounding pharmacies which by law should be converted to Outlook Therapeutics' LYTENAVA, if FDA approved*
- **Potential FDA approval August 29, 2023 as the first FDA approved ophthalmic formulation of bevacizumab**
- **Received validation of Marketing Authorization Application by European Medical Agency**
- **Current capital expected to fund operations through anticipated FDA approval of ONS-5010 in the third calendar quarter of 2023²**
- **Management team with proven ophthalmic commercial launch expertise**
 - *Leveraging strategic commercialization agreement with AmerisourceBergen to preserve capital and enhance commercial reach*

Source: Company reports.

Exhibit 7: NORSE ONE and THREE Studies Results

NORSE ONE and NORSE THREE Results



Completed Clinical Experience Trial

Demonstrated anticipated safety and efficacy signals consistent with previously published results for ophthalmic use of bevacizumab

Trial Highlights:

- Desired proportion of 3-line visual acuity gainers achieved
- Desired mean gain in visual acuity achieved
- Zero ocular inflammation observed
- Safety was comparable to published bevacizumab studies, such as CATT



Open-Label Safety Study

Positive safety profile reinforces previously reported safety data for ONS-5010 (bevacizumab-vikg)

Trial Highlights:

- Provided adequate number of patient exposure required for BLA submission
- No unexpected safety trends
- Zero cases of ocular inflammation, a concern that has emerged for other anti-VEGF therapies to treat retinal conditions

Source: Company reports.

Exhibit 8: NORSE TWO Pivotal Trial



Pivotal Trial

2nd Registration Trial



Trial Highlights:


- Randomized masked controlled trial
- ONS-5010 (bevacizumab-vikg) vs LUCENTIS® (ranibizumab)
- 228 patients enrolled
- Trial conducted in the United States
- Trial arms included >95% treatment-naïve patients

Source: Company reports.

Exhibit 9: NORSE TWO Study Conclusion

Superiority Phase 3 Pivotal Study Design

12-Month Study of Safety and Efficacy of ONS-5010 in Subjects with Wet AMD Study Design and Statistical Analysis Plan Agreed to by U.S. FDA



Study Eye Characteristics

- Active, primary CNV due to wet AMD
- Treatment-naïve
- BCVA: 20/50 – 20/320


Key Study Outcomes

- Proportion of subjects who gain ≥ 15 letters in BCVA
- Mean change in BCVA from baseline to Month 11
- Frequency and incidence of AEs



Primary Endpoint Met with Statistically Significant, Clinically Relevant Results¹

Characteristic	Statistic	ONS-5010 (n=113)	Ranibizumab (n=115)
Intent-to-Treat Pop.			
Number of Subjects	n/N (%)	45/108 (41.7)	24/104 (23.1)
Risk Difference		0.1859	
95% CI		(0.0442, 0.3086)	
p-value		0.0052	
Per Protocol Pop.			
Number of Subjects	n/N (%)	34/83 (41.0)	18/73 (24.7)
Risk Difference		0.1631	
95% CI		(0.0120, 0.3083)	
p-value		0.0409	



Source: Company reports.

Exhibit 10: NORSE TWO Study Design

NORSE TWO Pivotal Trial Design



Randomized masked controlled trial with 228 subjects




ONS-5010 (bevacizumab-vikg) administered monthly X 12



LUCENTIS dosing arm (PIER dosing) – Three initial monthly injections followed by fixed quarterly dosing



Primary endpoint difference in proportion of subjects gaining 15 letters of BCVA at Day 330



Source: Company reports.

Exhibit 11: NORSE ONE Study

NORSE ONE

First Registration,
Clinical Experience Study

Phase 3 Clinical Program

- Positive proof-of-concept
- Demonstrated anticipated safety and efficacy consistent with previously published results for ophthalmic bevacizumab

Study Highlights:

- Randomized Masked Controlled Trial
- ONS-5010 vs LUCENTIS® (ranibizumab)
- 61 subjects enrolled
- Study conducted in Australia
- Expected to support planned new U.S. BLA filing in 2021

Source: Company reports.

Exhibit 12: NORSE THREE Safety Study



Completed
Open-Label Safety Study
Supports BLA Requirements



Positive safety profile reported in NORSE 3 reinforces previously reported safety data for ONS-5010 ophthalmic bevacizumab

No unexpected safety trends, safety profile consistent with prior published data on the use of bevacizumab for ophthalmic conditions

Zero cases of ocular inflammation in NORSE 3, a concern that has emerged for other anti-VEGF therapies to treat retinal conditions

Trial Highlights:

- Open-label safety study
- Enrolled 197 subjects with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) or branch retinal vein occlusion (BRVO)
- Subjects received three doses of ONS-5010 ophthalmic bevacizumab over a three-month period
- Conducted to ensure adequate number of safety exposures to ONS-5010 ophthalmic bevacizumab

Source: Company reports.

Exhibit 13: NORSE SEVEN Study (ongoing currently)

NORSE SEVEN
Pre-Filled Syringe
Vials Versus Pre-Filled Syringe



Trial Highlights:

- 3-month study to compare the safety of ONS-5010 in vials versus Outlook Therapeutics investigational pre-filled syringe
 - Vial arm (n= has been fully enrolled and is now complete)
- Enrolling ~120 subjects with visual impairment due to retinal disorders
 - Wet AMD
 - BRVO
 - DME

Source: Company reports.

Exhibit 14: Outlook Therapeutics Stock Price (5-years)


Source: <https://bigcharts.marketwatch.com/>

Exhibit 15: Consensus Expectations (as of February 14, 2023)

	Revenue (mil)			EPS	
	2022A	2023E		2022A	2023E
Q1 Dec	\$0A	\$0E	Q1 Dec	\$(0.08)A	(0.06)E
Q2 Mar	\$0A		Q2 Mar	\$(0.09)A	
Q3 Jun	\$0A		Q3 Jun	\$(0.08)A	
Q4 Sep	\$0A		Q4 Sep	\$(0.06)A	
Total	\$0A	\$1E	Total	\$(0.31)A	\$(0.28)E

*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.

Source: Company report, Refinitiv, and Ascendant Capital Markets estimates

FINANCIAL MODEL

Outlook Therapeutics, Inc.

Income Statement (\$ mils)	Dec-20	Mar-21	Jun-21	Sep-21	2021	Dec-21	Mar-22	Jun-22	Sep-22	2022	Dec-22	Mar-23	Jun-23	Sep-23	2023	Dec-23	Mar-24	Jun-24	Sep-24	2024
Fiscal Year End: September 30	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Total Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	3.0	4.0	8.0
Cost of Revenues					0.0					0.0					0.0					0.0
Gross Profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	3.0	4.0	8.0
Research and development	11.9	8.5	8.5	9.9	39.0	9.9	12.2	11.2	9.0	42.3	9.9	8.0	7.0	6.0	30.9	5.0	5.0	5.0	5.0	20.0
General and administrative	2.2	4.1	2.9	3.5	12.8	3.3	6.7	5.8	5.0	20.7	5.8	6.0	7.0	7.0	25.8	8.0	9.0	10.0	11.0	38.0
Restructuring and other					0.0					0.0					0.0					0.0
Total operating expenses	14.2	12.6	11.5	13.4	51.7	13.1	18.9	17.0	14.0	63.1	15.7	14.0	14.0	13.0	56.7	13.0	14.0	15.0	16.0	58.0
Operating income (loss)	(14.2)	(12.6)	(11.5)	(13.4)	(51.7)	(13.1)	(18.9)	(17.0)	(14.0)	(63.1)	(15.7)	(14.0)	(14.0)	(13.0)	(56.7)	(13.0)	(13.0)	(12.0)	(12.0)	(50.0)
Interest income (expense)	(0.2)	(0.3)	(0.3)	(0.3)	(0.9)	(0.4)	(0.4)	(0.4)	(0.4)	(1.5)	(2.4)	(2.5)	(2.5)	(2.5)	(9.9)	(2.5)	(2.5)	(2.5)	(2.5)	(10.0)
Other income (expense)	(0.1)	(0.2)	(0.5)	0.3	(0.5)	(1.0)	(0.4)	(0.2)	0.0	(1.5)	(0.5)				(0.5)					0.0
Income before income taxes	(14.5)	(13.1)	(12.2)	(13.4)	(53.2)	(14.5)	(19.7)	(17.5)	(14.3)	(66.0)	(18.7)	(16.5)	(16.5)	(15.5)	(67.2)	(15.5)	(15.5)	(14.5)	(14.5)	(60.0)
Income taxes		0.0	0.2	0.2	0.2		0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss)	(14.5)	(13.1)	(12.2)	(13.6)	(53.4)	(14.5)	(19.7)	(17.5)	(14.3)	(66.1)	(18.7)	(16.5)	(16.5)	(15.5)	(67.2)	(15.5)	(15.5)	(14.5)	(14.5)	(60.0)
Nonrecurring/noncash adjustments					0.0					0.0					0.0					0.0
Net income (pro forma)	(14.5)	(13.1)	(12.2)	(13.6)	(53.4)	(14.5)	(19.7)	(17.5)	(14.3)	(66.1)	(18.7)	(16.5)	(16.5)	(15.5)	(67.2)	(15.5)	(15.5)	(14.5)	(14.5)	(60.0)
EBITDA																				
Shares, Basic	121.7	150.7	168.4	175.3	152.7	188.2	219.1	220.5	220.8	212.1	227.4	257.0	257.1	257.2	249.7	257.2	257.3	257.4	257.5	257.4
Shares, Diluted	121.7	150.7	168.4	175.3	152.7	188.2	219.1	220.5	220.8	212.1	227.4	257.0	257.1	257.2	249.7	257.2	257.3	257.4	257.5	257.4
EPS Basic (Pro forma)	(\$0.12)	(\$0.09)	(\$0.07)	(\$0.08)	(\$0.35)	(\$0.08)	(\$0.09)	(\$0.08)	(\$0.06)	(\$0.31)	(\$0.08)	(\$0.06)	(\$0.06)	(\$0.06)	(\$0.27)	(\$0.06)	(\$0.06)	(\$0.06)	(\$0.06)	(\$0.23)
EPS Diluted (Pro forma)	(\$0.12)	(\$0.09)	(\$0.07)	(\$0.08)	(\$0.35)	(\$0.08)	(\$0.09)	(\$0.08)	(\$0.06)	(\$0.31)	(\$0.08)	(\$0.06)	(\$0.06)	(\$0.06)	(\$0.27)	(\$0.06)	(\$0.06)	(\$0.06)	(\$0.06)	(\$0.23)
Margins																				
Gross margin	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	100%	100%	100%	#DIV/0!	100%	100%	100%	100%	100%
Research and development	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	500%	167%	125%	250%
General and administrative	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	900%	333%	275%	475%
Operating margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	-1300%	-400%	-300%	-625%
Tax rate, GAAP	0%	0%	0%	-1%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	-1550%	-483%	-363%	-750%
YYY % change																				
Total Revenue	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
Gross margin	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
Research and development	104%	95%	1%	30%	48%	-17%	43%	32%	-10%	9%	0%	-35%	-38%	-33%	-27%	-49%	-38%	-29%	-17%	-35%
General and administrative	-4%	109%	-11%	47%	28%	46%	63%	97%	43%	62%	78%	-10%	21%	40%	25%	37%	50%	43%	57%	47%
Operating income (loss)	73%	87%	-3%	34%	40%	-7%	50%	48%	4%	22%	19%	-26%	-18%	-7%	-10%	-17%	-7%	-14%	-8%	-12%
Net income (loss)	-22%	-25%	305%	37%	9%	0%	50%	44%	5%	24%	29%	-16%	-6%	8%	2%	-17%	-6%	-12%	-6%	-11%
EPS Diluted (Pro forma)	-57%	-35%	-34%	5%	-25%	-35%	3%	10%	-16%	-11%	7%	-29%	-19%	-7%	-14%	-27%	-6%	-12%	-7%	-13%

Source: Company reports and Ascendant Capital Markets estimates.

Outlook Therapeutics, Inc.

Balance Sheet (\$ mils)	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24
Fiscal Year End: September 30	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Assets																
Cash and cash equivalents	5.6	37.2	19.7	14.5	70.2	58.4	26.0	17.4	52.3	37.2	22.1	8.2	(5.9)	(20.0)	(33.1)	(46.2)
Short term investments										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts receivable, net										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income taxes										0.0	0.0	0.0	0.0	0.0	0.0	0.0
<u>Prepaid expenses and other</u>	<u>5.5</u>	<u>6.6</u>	<u>12.2</u>	<u>7.0</u>	<u>7.3</u>	<u>8.1</u>	<u>11.5</u>	<u>10.1</u>	<u>9.3</u>	<u>9.3</u>	<u>9.3</u>	<u>9.3</u>	<u>9.3</u>	<u>9.3</u>	<u>9.3</u>	<u>9.3</u>
Total current assets	11.0	43.8	31.9	21.5	77.5	66.5	37.5	27.5	61.7	46.6	31.5	17.6	3.5	(10.6)	(23.7)	(36.8)
Long term securities/investments				0.9	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
Property and equipment, net	0.3	0.2	0.2	0.2	0.1	0.1	0.0			(0.0)	(0.0)	(0.0)	(0.0)	(0.1)	(0.1)	(0.1)
Intangibles, net										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	<u>1.2</u>	<u>1.1</u>	<u>0.8</u>	<u>0.3</u>	<u>0.3</u>	<u>0.2</u>	<u>0.2</u>	<u>0.2</u>	<u>0.2</u>	<u>0.2</u>	<u>0.2</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>
Total assets	12.5	45.1	32.9	22.8	78.7	67.7	38.6	28.5	62.7	47.6	32.5	18.4	4.3	(9.8)	(23.0)	(36.1)
Liabilities and stockholders' equity																
Accounts payable	3.3	6.3	2.7	2.2	2.5	4.2	2.5	3.5	4.2	4.2	4.2	4.2	4.2	4.2	4.2	4.2
Accrued expenses	6.3	4.5	3.5	1.7	2.8	2.5	3.6	3.4	9.0	9.0	9.0	9.0	9.0	9.0	9.0	9.0
Deferred revenue										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9	1.9
Other	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<u>Short term debt</u>	<u>0.5</u>	<u>11.2</u>	<u>11.5</u>	<u>0.9</u>	<u>12.7</u>	<u>22.8</u>	<u>10.5</u>	<u>10.9</u>		<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>
Total current liabilities	12.1	23.9	19.6	6.8	19.9	31.4	18.4	19.7	15.1	15.1	15.1	15.1	15.1	15.1	15.1	15.1
Deferred income taxes										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities	0.2	0.4	0.4	0.5	0.3	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred revenue										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<u>Long term debt</u>	<u>10.7</u>	<u>0.1</u>		<u>10.9</u>	<u>9.6</u>				<u>31.8</u>	<u>31.8</u>	<u>31.8</u>	<u>31.8</u>	<u>31.8</u>	<u>31.8</u>	<u>31.8</u>	<u>31.8</u>
Total other liabilities	10.9	0.6	0.5	11.5	9.9	0.3	0.1	0.1	31.8	31.8	31.8	31.8	31.8	31.8	31.8	31.8
Preferred stock										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common stock	1.3	1.7	1.7	1.8	2.2	2.3	2.3	2.3	2.6	4.0	5.4	6.7	8.1	9.5	10.9	12.3
Additional paid-in capital	292.4	336.2	340.5	345.7	403.9	410.8	412.4	415.4	440.8	440.8	440.8	440.8	440.8	440.8	440.8	440.8
Retained earnings	(304.2)	(317.3)	(329.5)	(342.9)	(357.3)	(377.1)	(394.6)	(408.9)	(427.6)	(444.1)	(460.6)	(476.1)	(491.6)	(507.1)	(521.6)	(536.1)
Treasury stock										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accumulated other comprehensive income										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other										0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total stockholders' equity	(10.5)	20.7	12.7	4.6	48.8	36.0	20.1	8.7	15.8	0.7	(14.5)	(28.6)	(42.7)	(56.8)	(69.9)	(83.0)
Total stockholders' equity and liabilities	12.5	45.1	32.9	22.8	78.7	67.7	38.6	28.5	62.7	47.6	32.5	18.4	4.3	(9.8)	(23.0)	(36.1)

Balance Sheet Drivers

	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24	Jun-24	Sep-24
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1A	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Book & Cash Value (per share)																
Book Value per Share (diluted)	-\$0.09	\$0.14	\$0.08	\$0.03	\$0.26	\$0.16	\$0.09	\$0.04	\$0.07	\$0.00	-\$0.06	-\$0.11	-\$0.17	-\$0.22	-\$0.27	-\$0.32
Cash per Share (diluted)	\$0.05	\$0.25	\$0.12	\$0.09	\$0.38	\$0.27	\$0.12	\$0.08	\$0.23	\$0.15	\$0.09	\$0.04	-\$0.02	-\$0.07	-\$0.13	-\$0.18
Net cash per Share (diluted)	-\$0.05	\$0.17	\$0.05	\$0.02	\$0.26	\$0.17	\$0.07	\$0.03	\$0.09	\$0.02	-\$0.03	-\$0.09	-\$0.14	-\$0.20	-\$0.25	-\$0.30

Source: Company reports and Ascendant Capital Markets estimates

Outlook Therapeutics, Inc.


Cash Flow Statement (\$ mils)	Dec-20	Mar-21	Jun-21	Sep-21	2021	Dec-21	Mar-22	Jun-22	Sep-22	2022	Dec-22	Mar-23	Jun-23	Sep-23	2023	Dec-23	Mar-24	Jun-24	Sep-24	2024	
Fiscal Year End: September 30	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E	
Cash flow from operating activities																					
Net income	(14.5)	(13.1)	(12.2)	(13.4)	(53.2)	(14.5)	(19.7)	(17.5)	(14.3)	(66.1)	(18.7)	(16.5)	(16.5)	(15.5)	(67.2)	(15.5)	(15.5)	(14.5)	(14.5)	(60.0)	
Depreciation	0.1	0.1	0.0	0.1	0.3	0.1	0.1	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Amortization					0.0					0.0					0.0					0.0	
Debt related amortization expen	0.1	0.2	0.2	0.3	0.9	0.3	0.4	0.4	0.5	1.7	1.4				1.4					0.0	
Stock comp	1.2	1.1	1.2	1.4	4.9	1.2	3.8	1.4	1.4	7.7	1.4	1.4	1.4	1.4	5.6	1.4	1.4	1.4	1.4	5.6	
Deferred income taxes					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Provision for bad debts					0.0					0.0					0.0					0.0	
Change in fair value of warrant l	0.1	0.2	0.0	0.1	0.5	(0.1)	0.4	0.1	(0.9)	(0.5)	(0.0)				(0.0)					0.0	
Writedowns and impairments	(0.7)	0.2			(0.6)			1.0	(0.1)	0.9					0.0					0.0	
Other gains/losses			0.4	(0.4)	0.0	1.0	0.0	(1.0)	1.0	1.1	0.6				0.6					0.0	
Other	(0.0)	0.0			0.0					0.0					0.0					0.0	
Changes in operating assets and liabilities:																					
Accounts receivable					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Prepaid expenses & other curre	0.0	(1.4)	(5.6)	5.2	(1.7)	(0.3)	(0.8)	(3.4)	1.4	(3.1)	0.8	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	
Income tax					0.0					0.0					0.0					0.0	
Other assets	0.1		0.0	(0.0)	0.1	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	
Accounts payable	0.9	2.7	(3.5)	(0.4)	(0.2)	0.2	1.8	(1.7)	1.0	1.3	0.7	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	
Accrued expenses	(0.7)	(1.9)	(1.0)	(1.8)	(5.3)	1.0	(0.2)	(0.5)	(0.2)	0.2	5.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.0	
Deferred revenue					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Other liabilities		(0.1)	0.1		0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Net cash (used in) provided by	(13.3)	(11.7)	(20.2)	(9.0)	(54.3)	(11.0)	(14.3)	(21.1)	(10.3)	(56.7)	(8.9)	(15.1)	(15.1)	(13.9)	(53.0)	(14.1)	(14.1)	(13.1)	(13.1)	(54.4)	
Cash flow from investing activities																					
Purchases of property and equipment					0.0					0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Purchases of short-term investments					0.0					0.0					0.0					0.0	
Acquisitions					0.0					0.0					0.0					0.0	
Other					0.0					0.0					0.0					0.0	
Net cash used in investing activ	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Cash flow from financing activities																					
Issuance of debt	10.0				10.0	10.0				10.0	30.0	0.0	0.0	0.0	30.0	0.0	0.0	0.0	0.0	0.0	
Repayment of debt	(3.6)	(0.0)	(0.0)	(0.0)	(3.7)	(1.0)	(0.3)	(11.6)	(0.0)	(12.9)	(10.8)				(10.8)					0.0	
Issuance of stock	39.8	2.7	3.8	3.8	46.3	57.7	2.7	0.3	1.6	62.3	24.6	0.0	0.0	0.0	24.6	0.0	0.0	0.0	0.0	0.0	
Repurchase of common stock					0.0					0.0					0.0					0.0	
Proceeds from stock option exercises		3.6		0.0	3.6	0.0	0.2	0.0	0.0	0.2					0.0					0.0	
Other					0.0					0.0					0.0					0.0	
Dividends and distributions					0.0					0.0					0.0					0.0	
Cash provided by (used in) fina	6.4	43.3	2.7	3.8	56.2	66.7	2.6	(11.3)	1.6	59.6	43.8	0.0	0.0	0.0	43.8	0.0	0.0	0.0	0.0	0.0	
Effect of exchange rate on cash					0.0					0.0					0.0					0.0	
Net increase (decrease) in cash	(7.0)	31.6	(17.5)	(5.2)	1.9	55.7	(11.7)	(32.4)	(8.6)	2.9	34.9	(15.1)	(15.1)	(13.9)	(9.2)	(14.1)	(14.1)	(13.1)	(13.1)	(54.4)	
Beginning cash and equivalents	12.5	5.6	37.2	19.7	12.5	14.5	70.2	58.4	26.0	14.5	17.4	52.3	37.2	22.1	17.4	8.2	(5.9)	(20.0)	(33.1)	8.2	
Ending cash and equivalents	5.6	37.2	19.7	14.5	14.5	70.2	58.4	26.0	17.4	17.4	52.3	37.2	22.1	8.2	8.2	(5.9)	(20.0)	(33.1)	(46.2)	(46.2)	

Source: Company reports and Ascendant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

Outlook Therapeutics, Inc.



Source: <https://bigcharts.marketwatch.com/>

Report	Date	Rating	Price Target
1	4/22/2019	B	4.00
2	5/16/2019	B	3.00
3	8/20/2019	B	4.00
4	12/22/2019	B	3.50
5	1/29/2020	B	3.75
6	2/20/2020	B	3.50
7	5/21/2020	B	3.25
8	8/21/2020	B	4.00
9	8/31/2020	B	3.25
10	1/6/2021	B	3.50
11	2/17/2021	B	5.00
12	5/22/2021	B	6.00
13	9/6/2021	B	7.00
14	12/23/2021	B	7.25
15	3/2/2022	B	7.50
16	5/27/2022	B	7.75
17	8/17/2022	B	7.00

- Ascendant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered

companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech stocks, and changes in consumer or government priorities for healthcare.

Ascendant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of January 15, 2023)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	44	98%	18	41%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	45	100%	18	40%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.